https://doi.org/10.4081/hmr.v1i11.353

Thalidomide plus dexamethasone as initial therapy for multiple myeloma: overview of Mayo Clinic and Eastern Cooperative Oncology Group experience

Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005
Published: June 5, 2009
Abstract Views: 139
PDF: 257
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Robert A. Kyle
support@pagepress.org
Vincent Rajkumar
Dexamethasone has been shown to produce a response in at least 45% of patients who are newly diagnosed with multiple myeloma (MM) and in approximately one quarter of patients with relapsed or refractory disease.1,2A synergistic effect between dexamethasone and thalidomide has been identified, which is illustrated by the efficacy of this combination in relapsed MM.3 Studies of thalidomide and dexamethasone used to treat patients who are newly diagnosed with MM have yielded response rates from 64% to 72%.4,5 These results and others suggest that the combination of thalidomide and dexamethasone is an effective treatment choice for patients with MM.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Kyle, R. A., & Rajkumar, V. (2009). Thalidomide plus dexamethasone as initial therapy for multiple myeloma: overview of Mayo Clinic and Eastern Cooperative Oncology Group experience. Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.353
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).